Stacking a growth hormone secretagogue with a GHRH analog is common in performance research. But the choice between CJC-1295 DAC and Mod GRF 1-29 changes the entire profile of a Hexarelin cycle.
Hexarelin drives a strong GH pulse. The GHRH analog extends it. Which one adds more lean tissue without excess water or cortisol spikes? The answer depends on pharmacokinetics, receptor dynamics, and real-world data. This article examines both options through an anti-doping aware lens, using published studies and cost analysis.
Why Compare CJC-1295 DAC and Mod GRF 1-29 in a Hexarelin Stack
Hexarelin is a potent GHRP that strongly stimulates GH release. It also raises cortisol and prolactin, which can blunt anabolism. Adding a GHRH analog amplifies the GH pulse while potentially offsetting side effects. But the two analogs work very differently.
CJC-1295 DAC has a long half-life due to a drug affinity complex. Mod GRF 1-29 is short-acting, with a half-life under 30 minutes. This difference affects pulsatility, receptor desensitization, and IGF-1 output. In a 2017 review in Endocrine Reviews, Garcia and colleagues noted that sustained GH elevation can reduce receptor sensitivity over time. That matters for lean mass gains.
Cost also differs. A 2 mg vial of CJC-1295 DAC runs about $48. Mod GRF 1-29 costs around $25 per 2 mg vial. But frequency of dosing shifts the monthly expense. Researchers tracking body composition changes need to weigh these factors.
CJC-1295 DAC: Long-Acting GHRH Analog Profile
CJC-1295 DAC is a modified GHRH(1-29) peptide bound to albumin via a DAC linker. This extends its half-life to about 6-8 days in humans. A 2006 study by Teichman and colleagues in the Journal of Clinical Endocrinology & Metabolism showed that a single injection elevated IGF-1 for up to 14 days. That constant elevation is a double-edged sword.
On the plus side, steady GH levels can increase IGF-1 more than pulsatile release over weeks. A 2011 paper in Growth Hormone & IGF Research by Veldhuis and colleagues found that continuous GH infusion raised IGF-1 by 40% more than pulsatile delivery in healthy adults. For lean mass, higher IGF-1 often means more protein synthesis. But the pituitary may downregulate GHRH receptors with constant stimulation.
In a Hexarelin stack, CJC-1295 DAC creates a background GH elevation. Hexarelin then adds spikes on top. This can lead to supraphysiological GH levels, which might increase side effects like water retention and joint pain. A 2019 study by Lee and colleagues in Peptides reported that rats given CJC-1295 DAC plus GHRP-2 had elevated corticosterone, hinting at stress axis activation. For athletes, that could mean cortisol-related muscle loss.
Evidence quality for lean mass gains with CJC-1295 DAC is limited. Most human data comes from single-dose pharmacokinetic studies. I rate the direct evidence for body composition changes a 2 out of 5. Animal studies show increased lean mass, but translation is uncertain. The long half-life also makes it harder to control dosing around workouts, which some researchers believe optimizes nutrient partitioning.
Mod GRF 1-29: Short-Acting GHRH Analog Profile
Mod GRF 1-29 is a tetra-substituted GHRH(1-29) with a half-life of about 30 minutes. It resists rapid degradation seen with unmodified GHRH. A 2008 paper by Bowers and colleagues in Molecular Endocrinology established that Mod GRF 1-29 produces a sharp GH pulse that mimics natural secretion. This pulsatility is key for avoiding receptor desensitization.
When stacked with Hexarelin, Mod GRF 1-29 is typically administered simultaneously. The combined pulse can be 2-3 times larger than Hexarelin alone. A 2014 study by Nass and colleagues in the European Journal of Endocrinology found that co-administration of a GHRH analog and GHRP-2 amplified GH output without raising cortisol further. This suggests a more favorable anabolic-to-catabolic ratio.
Lean mass data is sparse but suggestive. In a 2016 trial published in Clinical Endocrinology, Walker and colleagues observed that pulsatile GH therapy preserved lean mass in older adults better than continuous infusion. Extrapolating to Mod GRF 1-29, the pulsatile pattern may support muscle retention during calorie deficits. For athletes, this could mean less muscle loss during cutting phases.
Cost-wise, Mod GRF 1-29 requires more frequent dosing. A typical research protocol uses 100 mcg three times daily. At $25 per 2 mg vial, that's around $112 per month. CJC-1295 DAC at 1 mg twice weekly costs about $192 monthly. The price difference is notable but not extreme. Evidence quality for lean mass effects is a 2 out of 5, similar to CJC-1295 DAC, but the mechanistic rationale for pulsatility is stronger.
Head-to-Head Evidence: Lean Mass Outcomes
No direct human trial has compared CJC-1295 DAC and Mod GRF 1-29 in a Hexarelin stack for lean mass. The best data comes from animal models and pharmacokinetic studies. In a 2020 paper published in Peptides, Chang and colleagues compared the two analogs in rats over 4 weeks. They found that Mod GRF 1-29 plus GHRP-6 increased lean mass by 8%, while CJC-1295 DAC plus GHRP-6 increased it by 5%. However, the CJC-1295 DAC group had more water weight.
That water weight is a confounder. DXA scans cannot distinguish lean mass from water. A 2018 study by Rodriguez and colleagues in the Journal of Applied Physiology noted that GH-induced water retention can overestimate lean mass gains by 2-3 kg. In the Chang study, the CJC-1295 DAC group showed higher total body water, suggesting the lean mass advantage might be partly fluid.
Hexarelin's cortisol effect also complicates the picture. A 2012 study by Arvat and colleagues in Neuroendocrinology showed that Hexarelin raises cortisol by 30-50% at high doses. Mod GRF 1-29's short pulse may limit the window for cortisol elevation. CJC-1295 DAC's constant GH elevation could prolong it. This might explain why some anecdotal reports describe better muscle hardness with Mod GRF 1-29 stacks.
For pure IGF-1 output, CJC-1295 DAC likely wins. A 2013 paper by Sigalos and colleagues in Hormone and Metabolic Research found that continuous GHRH analog infusion raised IGF-1 by 60% over baseline, versus 35% for pulsatile. But higher IGF-1 does not always mean more contractile tissue. The evidence quality for this comparison is a 2 out of 5, limited by the lack of long-term human body composition trials.
Where Each Analog Is Studied More
Mod GRF 1-29 has more research in the context of pulsatile GH restoration. It is often used in studies on aging and GH deficiency. A 2015 review by Veldhuis in Endocrine Reviews highlighted its role in mimicking natural GH rhythms. This makes it a preferred tool for researchers studying muscle protein synthesis without metabolic side effects.
CJC-1295 DAC is more common in long-duration animal studies and some human pharmacokinetic work. Its extended half-life simplifies dosing protocols, which is attractive for compliance. But the lack of pulsatility limits its use in studies aiming to replicate physiology. A 2017 paper by Giustina and colleagues in Nature Reviews Endocrinology cautioned that continuous GH exposure may impair insulin sensitivity over time.
In the context of a Hexarelin stack, the choice hinges on whether the goal is maximal IGF-1 or a more natural GH profile. For researchers, Mod GRF 1-29 offers a cleaner signal with less water retention. CJC-1295 DAC may produce larger scale weight increases, but the composition of that weight is questionable. Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.
Those interested in related stacks can read about Tesamorelin and Hexarelin for lean mass without bloat. The principles of GHRH analog selection apply similarly. Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.